Asset Acquisition, Consideration Transferred

No definition available.

Name:	fold_AssetAcquisitionConsiderationTransferred
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Includes payments for achievement of certain clinical, regulatory and commercial milestones.

+ References

No definition available.

+ Details

Name:	fold_BusinessAssetAcquisitionConsiderationTransferredIncludingMilestonePayment
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of contingent consideration payable in a business asset acquisition upon achievement of certain clinical, regulatory and commercial milestones.

+ References

No definition available.

+ Details

Name:	fold_BusinessAssetAcquisitionContingentConsiderationMilestones
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of shares of equity interests issued or issuable to acquire entity.

+ References

No definition available.

+ Details

Name:	fold_BusinessAssetAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix:	fold_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

The company enrollment percent achieved during the year.

+ References

No definition available.

+ Details

Name:	fold_BusinessCombinationOfEnrollmentRate
Namespace Prefix:	fold_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the amount of milestone payment.

+ References

No definition available.

+ Details

Name:	fold_ContingentConsiderationMilestonePayment
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Income Tax Expense (Benefit) Due To Wind-Down

+ References

No definition available.

+ Details

Name:	fold_IncomeTaxExpenseBenefitDueToWindDown
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number Of Gene Therapy Programs For Neurologic LSDs Developed

+ References

No definition available.

+ Details

Name:	fold_NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped
Namespace Prefix:	fold_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).

+ References

No definition available.

+ Details

Name:	fold_PaymentsToAcquireBusinessAssets
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of research and development expenses due to wind-down of operations.

+ References

No definition available.

+ Details

Name:	fold_ResearchAndDevelopmentExpensesDueToWindDown
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of research expense charged to statement of operations for stock issued in assets acquisition transaction.

+ References

No definition available.

+ Details

Name:	fold_ResearchExpenseForStockIssuanceInAssetAcquisition
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue Recognition, Milestone Method, Contingent On Development

+ References

No definition available.

+ Details

Name:	fold_RevenueRecognitionMilestoneMethodContingentOnDevelopment
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue Recognition, Milestone Method, Contingent On Submission And Approval Milestones

+ References

No definition available.

+ Details

Name:	fold_RevenueRecognitionMilestoneMethodContingentOnSubmissionAndApprovalMilestones
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue Recognition, Milestone Method, Maximum Expected Payment Over Next Four Years

+ References

No definition available.

+ Details

Name:	fold_RevenueRecognitionMilestoneMethodMaximumExpectedPaymentOverNextFourYears
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of selling, general and administrative costs due to wind-down of operations.

+ References

No definition available.

+ Details

Name:	fold_SellingGeneralAndAdministrativeCostsDueToWindDown
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228

+ Details

Name:	us-gaap_AssetImpairmentCharges
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph b
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.

+ References

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044

+ Details

Name:	us-gaap_ContractWithCustomerAssetNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=fold_MilestonePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=fold_CallidusBiopharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_FixedAssetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=fold_MiamedIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=fold_SciodermIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=fold_ChangesInFairValueOfContingentConsiderationPayableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalRegulatoryAndCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	fold_AssetAcquisitionAxis=fold_CelenexMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=fold_NationwideChildrensHospitalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Acquisitions (Details) $ in Thousands	1 Months Ended			3 Months Ended		12 Months Ended
Acquisitions (Details) $ in Thousands	Sep. 30, 2018 USD ($) program	Apr. 30, 2017 USD ($)	Jul. 31, 2016 USD ($) shares	Sep. 30, 2017 USD ($)	Mar. 31, 2017	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Acquisitions
Number of gene therapy programs for neurologic LSDs developed \| program	10
Charges to research expense for stock issued in asset acquisition						$ 0	$ 0	$ 4,607
Loss on impairment of assets						0	465,427	0
Changes in fair value of contingent consideration payable						3,300	(234,322)	6,760
Contingent consideration payable						19,700	25,400
Contingent consideration payable						0	8,400
Contingent consideration payable, non-current portion						19,700	17,000
Milestone Payment\ \| Callidus
Acquisitions
Milestone payment						9,000
Fixed assets
Acquisitions
Loss on impairment of assets							1,700
MiaMed Inc
Acquisitions
Asset acquisition, total consideration, stock and cash			$ 6,500
Asset acquisition, cash consideration paid			1,800
Asset acquisition, potential aggregate deal value			$ 89,500
Charges to research expense for stock issued in asset acquisition								$ 6,500
MiaMed Inc \| Amicus \| Common Stock
Acquisitions
Consideration paid in common stock \| shares			825,603
Scioderm
Acquisitions
Enrollment rate					100.00%
Milestone payment		$ 10,000
Loss on impairment of assets							$ 463,700
Changes in fair value of contingent consideration payable				$ 254,700
Selling , general and administrative costs due to wind-down				400
Research and development expenses due to wind-down				8,100
Income tax expense (benefit) due to wind-down				$ (164,700)
Callidus
Acquisitions
Contingent consideration payable						28,700
Contingent consideration payable						9,000
Contingent consideration payable, non-current portion						19,700
Callidus \| Changes in fair value of contingent consideration payable
Acquisitions
Changes in fair value of contingent consideration payable						$ 3,300
Clinical, Regulatory and Commercial milestones \| MiaMed Inc \| Maximum
Acquisitions
Contingent consideration payable upon achievement of milestones			$ 83,000
Celenex
Acquisitions
Research and development expense	$ 100,000
Contingent consideration based on the achievement of certain milestones	15,000
Contingent consideration based on the achievement of regulatory milestones	262,000
Maximum payment under contingent consideration over the next 4 years	75,000
Celenex \| Nationwide Children's Hospital
Acquisitions
Contingent consideration based on the achievement of certain milestones	$ 7,800